Patents Assigned to Genentech, Inc.
  • BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
    Publication number: 20240199594
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Application
    Filed: August 4, 2023
    Publication date: June 20, 2024
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle BRAUN, Emily HANAN, Steven T. Staben, Robert Andrew HEALD, Calum MACLEOD, Richard ELLIOTT
  • MODIFIED CELLS FOR THE PRODUCTION OF A RECOMBINANT PRODUCT OF INTEREST
    Publication number: 20240190944
    Abstract: The present disclosure relates to cells (e.g., Chinese Hamster Ovary (CHO) cells) that are modified to reduce or eliminate the expression of certain endogenous cellular proteins, and methods of using such cells in the production of a recombinant product of interest, e.g., a recombinant protein, a recombinant viral particle, or a recombinant viral vector. These modifications were specifically chosen to generate engineered cells with desired traits in several key areas, including improved cell culture performance (e.g., higher viability and product titers).
    Type: Application
    Filed: November 20, 2023
    Publication date: June 13, 2024
    Applicant: Genentech, Inc.
    Inventors: Shahram MISAGHI, Brian Megia Castellano, Danming Tang, Avi J. Ashkenazi, Bradley R. Snedecor
  • Dual specific antibodies for binding interleukin 4 (IL4) and interleukin 5 (IL5)
    Patent number: 12006360
    Abstract: The invention provides dual specific antibodies capable of binding interleukin 4 (IL4) and interleukin 5 (IL5) and methods of making and using such antibodies. In general, the dual specific antibodies capable of binding IL4 and IL5 are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: June 11, 2024
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Chingwei V. Lee, Patrick Koenig
  • Cell-based assay for detecting anti-CD3 homodimers
    Patent number: 12007398
    Abstract: The present invention provides a cell-based assay for identifying and/or quantifying anti-CD3 homodimers in a composition comprising a T cell-dependent Bispecific antibody (TDB). In some aspects, the invention T cells comprising a T cell activation responsive reporter are contacted with the TDB to detect the presence of anti-CD3 homodimers. Compositions of reporter T cells and kits are also contemplated.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: June 11, 2024
    Assignee: GENENTECH, INC.
    Inventor: Kendall Carey
  • Therapeutic compounds and methods
    Patent number: 12006331
    Abstract: The invention provides a compound of formula (I): or a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 have any of the values described in the specification, as well as compositions comprising a compound of formula (I) or a prodrug thereof, or a pharmaceutically acceptable salt thereof. The compounds are agonists of glycolytic enzyme phosphofructokinase-1 liver type and are useful for treating diseases associated with the activity of glycolytic enzyme phosphofructokinase-1 liver type, such as cancer, diabetes, sepsis, and septic shock.
    Type: Grant
    Filed: July 12, 2022
    Date of Patent: June 11, 2024
    Assignee: GENENTECH, INC.
    Inventors: Samantha Alyson Green, Jessica Marie Grandner, Steven Thomas Staben, Neri Amara, Vishva M. Dixit, Elisia Villemure
  • Chimeric ABC Transporters and Screening Methods
    Publication number: 20240183860
    Abstract: The present disclosure relates to chimeric ABC transporter proteins and methods of screening for molecules that bind to the periplasmic, extracellular, and/or luminal face of an ABC transporter protein using the chimeric ABC transporters. For example, in some embodiments, screening methods involve providing a chimeric ABC transporter in which one or more regions of the periplasmic, extracellular, and/or luminal face of the ABC transporter are substituted with one or more equivalent regions of the periplasmic, extracellular, and/or luminal face of a different ABC transporter and selecting for molecules that bind to the ABC transporter but do not bind to the chimeric ABC transporter. The disclosure also relates to molecules that bind to the periplasmic, extracellular, and/or luminal face of an ABC transporter protein, for example, identified in such screens.
    Type: Application
    Filed: October 25, 2023
    Publication date: June 6, 2024
    Applicant: Genentech, Inc.
    Inventors: Jian Mehr-Dean Payandeh, Patrick C. Reid, Christian Nathaniel Cunningham, Evan Green, Christopher Koth, Vishal Verma
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
    Publication number: 20240180901
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: December 8, 2023
    Publication date: June 6, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak SAMPATH, Christian KLEIN, Wayne John FAIRBROTHER
  • Prevention of disulfide bond reduction during recombinant production of polypeptides
    Patent number: 11999791
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: May 1, 2023
    Date of Patent: June 4, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Tie2-binding agents and methods of use
    Patent number: 11999787
    Abstract: The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: June 4, 2024
    Assignee: Genentech, Inc.
    Inventors: Minhong Yan, Gu Zhang, Nicholas John Agard, Danielle Marie Dicara, Philip E. Hass, Julie Q. Hang, Erin L. Christensen, Robert Paul Morse, Sarah Sanowar, Vittal Shivva
  • Synthesis of a bis-mesylate salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide and intermediates thereto
    Patent number: 11999749
    Abstract: A manufacturing process to a bis-mesylate salt 1b of the pan-RAF inhibitor 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide. The process features a number of efficient key reactions, including a robust and scalable Pd-catalyzed carbonylation reaction to generate thienopyrimidine 2 and a highly chemoselective Pt/V/C-catalyzed nitro group reduction to access penultimate intermediate 7. The final amide coupling of 7 and 2 was accomplished by a mild and safe protocol employing N,N,N?,N?-tetramethylchloroformamidinium hexafluorophosphate (TCFH) as the coupling reagent, to produce a 1:1 adduct of the freebase and THF. The adduct afforded compound 1b with excellent yield, purity, and form stability on a multikilogram production scale after reaction with MsOH and recrystallization. The methods are able to produce a compound having upwards of 95% purity.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: June 4, 2024
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Francis Gosselin, Stefan G. Koenig, Eduardo V. Mercado-Marin, Andreas Stumpf, Daniel Zell, Haiming Zhang, Stephan Bachmann, Diane E. Carrera, Michael E. Dalziel, Yonghui Ge, Jie Zhang, Raphael Bigler, Laure Elizabeth Simone Finet, Regis Jean Georges Mondiere, Yuki Nakagawa
  • PROCESSES FOR SYNTHESIS OF SUBSTITUTED INDOLE INTERMEDIATES FOR THE SYNTHESIS OF SERD COMPOUNDS
    Publication number: 20240174678
    Abstract: Provided herein are processes for the preparation of compounds useful in the treatment of cancer.
    Type: Application
    Filed: December 5, 2023
    Publication date: May 30, 2024
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: HAIMING ZHANG, JIE XU, GEORG WUITSCHIK, REMY ANGELAUD, SEBASTIAN HEROLD, ALFRED STUTZ, TOBIAS BRUETSCH, JOHANNES BURKHARD
  • METHODS FOR TREATING SPINAL MUSCULAR ATROPHY
    Publication number: 20240173325
    Abstract: Provided are methods for the treatment of spinal muscular atrophy (SMA) in a fetal subject in need thereof comprising administering an amount of risdiplam to a carrier of the fetal subject. Administering the amount of risdiplam to the carrier of the fetal subject results in transplacental delivery to the fetal subject, resulting in an increase in SMN protein production.
    Type: Application
    Filed: October 13, 2023
    Publication date: May 30, 2024
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Richard S. Finkel, Heidemarie Kletzl, Lutz Mueller, Renata Siciliani Scalco, Gaurav Seth, Alexander Herbert Stephan
  • TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND A CDK4/6 INHIBITOR
    Publication number: 20240173306
    Abstract: Provided herein are combination therapies comprising GDC-9545 and a CDK4/6 inhibitor for treating locally advanced breast cancer or metastatic breast cancer.
    Type: Application
    Filed: January 26, 2024
    Publication date: May 30, 2024
    Applicant: Genentech, Inc.
    Inventors: Jennifer O'Hara LAUCHLE, Sandra MILAN, Melanie Carol SMITT, Marjorie C. GREEN
  • 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS
    Publication number: 20240174696
    Abstract: Disclosed are 2,8-diazaspiro[4.5]decane compounds, including (pyrido[3,4-d]pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane compounds, (2,6-naphthyridin-1-yl)-2,8-diazaspiro[4.5]decane compounds, and (1,7-naphthyridin-4-yl)-2,8-diazaspiro[4.5]decane compounds, that are inhibitors of LATS1/2, compositions containing these compounds, and methods for inhibiting LATS1/2 activity.
    Type: Application
    Filed: December 1, 2023
    Publication date: May 30, 2024
    Applicant: Genentech, Inc.
    Inventors: Steven John MCKERRALL, Alice Rose WONG, James John CRAWFORD, Wendy LEE, Kwong Wah LAI, Guillaume PELLETIER, Stéphanie ROY, Dana Krystin WINTER, Mikiko OKUMURA, Ruth Dorel
  • Therapeutic compounds
    Patent number: 11993599
    Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: May 28, 2024
    Assignee: GENENTECH, INC.
    Inventors: Elisia Villemure, Joachim Rudolph, Mingshuo Zeng
  • Adjuvant treatment of HER2-positive breast cancer
    Patent number: 11992529
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: May 28, 2024
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • PROCESS FOR THE PREPARATION OF BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS
    Publication number: 20240166595
    Abstract: Methods of making benzoxazepin oxazolidinone compounds as well as synthetic intermediates are described, including compound (10-2) and compound 18:
    Type: Application
    Filed: November 27, 2023
    Publication date: May 23, 2024
    Applicant: Genentech, Inc.
    Inventors: Rémy Angelaud, Tobias Bruetsch, Francis Gosselin, Chong Han, Alfred Stutz
  • IDENTIFICATION AND QUANTITATION OF RESIDUAL HOST CELL PROTEINS IN PROTEIN SAMPLES
    Publication number: 20240168036
    Abstract: The present disclosure relates to highly sensitive methods for determining the identity and quantity of one or more proteins in a sample. For example, the present disclosure provides methods for the highly sensitive identification and quantitation of residual host cell proteins in protein samples and can be adapted to identify and quantify proteins in either a targeted or a target-agnostic manner and can be modified to achieve a range of sensitivities appropriate for distinct use cases.
    Type: Application
    Filed: December 1, 2023
    Publication date: May 23, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.
    Inventors: Jia Guo, Regina Kufer, Delia Li, Feng Yang, Inn Huam Yuk, Jinhua Zhang, Lance J. Cadang, Lu Dai
  • Prevention of disulfide bond reduction during recombinant production of polypeptides
    Patent number: 11987638
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: January 11, 2024
    Date of Patent: May 21, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Prevention of disulfide bond reduction during recombinant production of polypeptides
    Patent number: 11987637
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: January 11, 2024
    Date of Patent: May 21, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt